Drug Development
The latest news about Drug Development: headlines, AI summaries and the full story from every source.
- Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Development
- Cinclus Pharma Expects HEEALING1 Top-Line Results Following Patient Randomization
- Proximal Ventures Raises $27.5 Million Debut Fund to Invest in AI-Driven Drug Development Services
- Johnson & Johnson's Caplyta Meets Primary Endpoints in Bipolar Mania Clinical Trial
- Xenon Pharmaceuticals Advances Azetukalner Regulatory Path and Announces X-FIRST Study Timeline
- Eli Lilly's Oral GLP-1 Foundayo Shows Significant Improvement in Sleep Apnea Phase 3 Trial
- Vir Biotechnology Reports Positive Phase 3 Trial Results for Chronic Hepatitis Delta Treatment
- Novartis to Halt Development of Ionis-Derived Heart Disease Therapy Following Clinical Trial Failure
- Cognition Therapeutics Plans Phase III Trial for Zervimesine in DLB by Mid-2027
- Palvella Reports Q3 2026 Financial Results and FDA Priority Review for QTORIN
- AbbVie and Nxera Pharma Enter $1.5 Billion Licensing Agreement for IBD Therapy
- Teva Pharmaceuticals Discontinues Phase 2 Emrusolmin Study for Multiple System Atrophy
- AbbVie Clinical Trial Shows Promising Results for Crohn's Disease Combination Therapy
- Acumen Pharmaceuticals Shares Plunge Following Failed Alzheimer's Clinical Trial
- Novartis Faces Future Patent Cliffs Despite Optimism for Remibrutinib
- Kymera Therapeutics Reports Q3 2026 Results and Positive Phase I Data for KT-579
- FDA Issues Draft Guidance to Accelerate Personalized Gene Therapy Development
- United Therapeutics Receives FDA Clearance for Phase 1 Trial of Treprostinil-Iloprost SMI
- Pfizer Announces Successful Late-Stage Trial for Multiple Myeloma Drug Elrexfio
- Acumen Pharmaceuticals Prepares for Phase II ALTITUDE-AD Trial Results in November
- Johnson & Johnson Reports 75% Tumor Response Rate in Early-Stage Prostate Cancer Trial
- ESMO Congress Highlights Oncology Breakthroughs Amid Market Volatility and Fed Uncertainty
- FDA Launches Rare Disease Framework Initiative
- Verastem's VS-7375 Shows Strong Anti-Tumor Activity in KRAS G12D-Mutant Cancers
- AbbVie releases phase 3 induction therapy data on injectable Skyrizi for Crohn's
- Bristol Myers Squibb Shares Drop Following Mixed Phase 3 Trial Results for Admilparant in IPF
- Roche's Experimental Eye Drug Shows Vision Improvements in Clinical Trials
- BridgeBio Reports Positive Phase 3 Trial Results for Rare-Disease Drug Encaleret
- Biohaven Licenses IgG Degrader Portfolio to Ono Pharmaceutical
- Argenx Announces Discontinuation of Late-Stage Trial, Stock Drops
- vTV Therapeutics' Sickle Cell Candidate HPPD Receives FDA Orphan Drug Designation
- Bausch + Lomb Advances Development of Oral Treatment for Dry AMD
- AbbVie's investigational obesity drug shows up to 9.8% weight loss in Phase 1 trial
- Merck Enters Global Licensing Agreement With SciBrunch Therapeutics
- Merck Withdraws BLA for Antibody-Drug Conjugate I-DXd in Small Cell Lung Cancer
- Acadia Pharmaceuticals Stock Drops After Mid-Stage Trial Failure
- Merck's Remigromig Shows Efficacy for Diabetic Macular Edema in Trial
- InnoCare Pharma Enters Licensing Deal with Eli Lilly Worth Up to $3.35 Billion
- Roivant Shares Drop After Immunovant Trial Fails
- Xenon Pharmaceuticals Stock Drops After Halting Enrollment in Depression Trials
- Xenon Pharmaceuticals Pauses Drug Trial, Sending Shares Down
- Novartis' Failed Cholesterol Drug Trial Raises Questions About Amgen and Eli Lilly's Experimental Treatments
- Novo Nordisk Halts Two Additional Heart Drug Trials
- Xenon Pharmaceuticals Halts Enrollment in Clinical Trials for Azetukalner Due to Side Effects
- Spyre Therapeutics (SYRE) Completes Monotherapy Phase in IBD Portfolio
- Jazz Pharmaceuticals Acquires Actio Biosciences for Potential Epilepsy Treatment
- Novartis' Clinical Failure Impacts Cardiovascular Drug Race and Eli Lilly
- Electra Therapeutics plans $341.9M IPO to fund Phase III trial for hyperinflammatory syndrome drug
- ORIC Initiates Phase 3 Trial for Prostate Cancer Drug Rinzimetostat
- Electra Therapeutics Aims for $977.6 Million Valuation with U.S. IPO